Venture Kick

Unomr develops novel nano-​micro technology based sensing approaches for diagnostics and drug discovery.

SightIn Health develops artificial intelligence-powered software for using portable ultrasound. It provides image analytics, usage guidance, and interpretation of patient's diagnosis. SightIn Health was founded in 2021 and is based in Geneva, Switzerland.

Avelo mission is to save lives by bringing fast and actionable infectious disease diagnoses to primary care.

YLAH specializes in creating web and mobile applications tailored for psychotherapists and their patients. The company focuses on developing technology that delivers individualized therapies, clinical assessments, and health monitoring. This digital tool enables therapists to enhance and scale their services effectively, improving the overall therapeutic experience for patients.

NexMR is a Swiss company offering key-in-hand solutions to improve the throughput and optimize the resources of NMR-drug discovery pipelines. NexMR’s technology is designed to be accessible to the most and to ease the addressing of challenging targets.

NexMR is a Swiss company offering key-in-hand solutions to improve the throughput and optimize the resources of NMR-drug discovery pipelines. NexMR’s technology is designed to be accessible to the most and to ease the addressing of challenging targets.

Sensemodi develops an AI-powered smart wearable device that assesses joint health, particularly focusing on the knee and other joints. By utilizing a combination of thermal, acoustic, and kinematic data, the device provides a quick evaluation of joint conditions. This innovative technology aims to prevent disabilities and reduce the socioeconomic burden associated with musculoskeletal disorders. The wearable allows users to conveniently monitor their joint health, facilitating access to improved healthcare treatments and promoting proactive management of joint-related issues.

Oncobit is focused on enhancing personalized cancer care through the development of precise and highly sensitive diagnostic and monitoring tests. The company combines technical expertise with proprietary software and engages in close clinical collaborations, initially concentrating on melanoma while maintaining the potential to expand its solutions to other cancer types. Oncobit's innovative approach aims to improve patient outcomes by providing comprehensive and sensitive tests that enable clinics to offer tailored therapies and diagnostics, ensuring that cancer monitoring keeps pace with advancements in treatment methodologies.

CompagOs is focused on enhancing cancer treatment for patients with bone cancer through an innovative in vitro diagnostic tool. Utilizing advanced 3D bioprinting technology, the company creates mineralized bone organoids that replicate the unique cancerous conditions of individual patients within a controlled laboratory environment. This allows for the assessment of drug reactions in a complex bone microenvironment, surpassing the limitations of traditional animal and 2D models. The platform not only aims to personalize treatment options for patients but also serves as a valuable research tool for clinical, pharmaceutical, and biotech sectors. By enabling researchers to evaluate drug efficacy in a realistic and patient-relevant context, CompagOs is positioned to drive advancements in oncology and improve patient outcomes.

Bone fractures involving a joint are complex in nature, resulting in difficult and time-consuming procedures for the treating orthopaedic surgeon. We provide fracture specific optimization of complex bone reconstruction. Our software solution ensures efficacy of personalized surgical planning, as well as “save and effective” patient-specific implant and instrument design, changing the treatment strategy from a subjective to an objective approach with more predictable outcomes. This could improve outcomes of 400,000 trauma patients, addressing a $1.2 B market. A Harvard Medical School surgeon directing the medical aspects, provides crucial credibility.

Rea Diagnostics specializes in developing non-invasive diagnostic technology aimed at assessing the risk of preterm birth. The company's primary product is a smart pad equipped with an embedded sensor that detects proteins indicative of labor. This device incorporates a microfluidic system, a biosensing unit, and a readout system, enabling the identification and quantification of biomarkers present in vaginal fluid. The results are communicated through a mobile application, allowing healthcare professionals to make timely and informed decisions regarding the risk of premature birth. Headquartered in Lausanne, Switzerland, Rea Diagnostics addresses the need for more efficient diagnostics in the preterm birth market, ultimately supporting better outcomes for mothers and infants.

Bone fractures involving a joint are complex in nature, resulting in difficult and time-consuming procedures for the treating orthopaedic surgeon. We provide fracture specific optimization of complex bone reconstruction. Our software solution ensures efficacy of personalized surgical planning, as well as “save and effective” patient-specific implant and instrument design, changing the treatment strategy from a subjective to an objective approach with more predictable outcomes. This could improve outcomes of 400,000 trauma patients, addressing a $1.2 B market. A Harvard Medical School surgeon directing the medical aspects, provides crucial credibility.

peakPCR develops Polymerase Chain Reaction (PCR) devices for research and private laboratories. peakPCR is a low-cost, small size device capable of performing real-time polymerase chain reaction (qPCR). PCR is a method widely used in molecular biology to duplicate DNA segments, with applications such as genotyping, mutation detection, forensics, and paternity testing. The Polymerase Chain Reaction (PCR) is a widely used molecular technique to make millions of copies of a DNA sample, with applications in a variety of fields such as medical diagnostics, biotechnology, and forensic sciences. We have analyzed the heat transfer limitations of conventional PCR machines. This has led to the design of a completely new sample holder with extremely high heating and cooling rates and a much lower sample volume, in order to cut analysis time from currently 1-2 h down to 10 minutes, and reagent consumption by 90%. Next to a first stand-alone desktop instrument, we have also developed a portable version that is battery-powered and that operates in conjunction with a smartphone. We aim to deploy these PCR devices to research and private laboratories at affordable prices.

Emovo Care SA, founded in 2020 and located in Lausanne, Switzerland, develops a robotic hand orthosis aimed at individuals with motor impairments resulting from stroke. The company is ISO 13485 certified and focuses on creating accessible robotic devices that facilitate movement at home for hemiparetic stroke patients. Their flagship product is an active orthosis designed to enable users to move their hands independently, enhancing rehabilitation efforts. The device is accompanied by a mobile application that tracks usage and motivates users, thereby providing value to patients, clinicians, and health insurers. The core technology behind the orthosis emerged from research conducted during a PhD program at EPFL, which garnered significant international media attention for its innovative approach to brain-computer interfaces. The product is expected to receive CE marking by 2022.

Nutrix is a Swiss health-tech company founded in 2019 and based in Basel. It specializes in developing a nanosensor that is placed on the tooth to measure glucose levels in saliva, providing a non-invasive method for users to monitor their health. This technology is integrated with an external application that tracks food intake and offers dietary advice, aiming to aid in the prevention of diabetes. Nutrix combines artificial intelligence with wearables to create cost-effective healthcare solutions. In 2025, the company plans to introduce CortiSense, a non-invasive cortisol monitoring sensor that has already received a CES Innovation Award, further expanding its portfolio of health monitoring technologies. Through its innovative approach, Nutrix enables users to manage their health conditions effectively without the need for frequent medical consultations.

epyMetrics AG is a Swiss health analytics company that specializes in developing diagnostic wearable solutions aimed at monitoring the body's heat balance. Incorporated in 2019 and based in Zurich, the company offers a comprehensive platform that enables users to continuously and non-invasively track their thermoregulation. Its technology detects early signs of heat stress, facilitating the prevention of heat-related accidents. The wearable device captures vital signs, including sweat rate and total sweat loss, providing crucial data that allows industries to identify the risk of heat exhaustion. By offering personalized safety benchmarks, epyMetrics aims to enhance safety protocols and reduce costs associated with heat-related incidents.

MimiX Biotherapeutics Sàrl, established in 2016 and based in La Tène, Switzerland, specializes in the development of biofabrication technology for therapeutic and diagnostic applications. The company focuses on creating an ultra-fast biomanufacturing process that enables the production of patient-specific biological tissue equivalents. This innovative approach supports regenerative medicine and personalized healthcare, allowing for tailored treatments that meet individual patient needs. By advancing tissue engineering techniques, MimiX Biotherapeutics aims to enhance the precision and effectiveness of medical interventions.

Selph is a medical technology company that focuses on developing a medical device that enables people to conduct a self-test for sexually transmitted diseases. It specializes in digital health, sensors, diagnostics, and medical services.

OptiChroniX is a Swiss digital health solution company focused on enhancing brain health through early intervention. The company develops digital health interventions that combine biomedical, behavioral, computing, and engineering research, which are accessible via smartphones. These interventions allow patients to personalize and monitor their brain health by integrating data from various wearables. By offering tailored coaching, OptiChroniX aims to improve health literacy and medication adherence, addressing modifiable risk factors linked to cognitive decline, particularly in patients with Alzheimer’s disease and related co-morbidities. The company's mission is to optimize lifestyle choices and make healthcare more effective, ultimately enhancing clinical outcomes and quality of life.

Testmate Health is a medtech startup and an award-winning spin-off of the University of Geneva, focused on developing innovative healthcare solutions. The company has created a smartphone-compatible test kit that can diagnose diseases with identifiable DNA or RNA sequences, providing results directly at home in just minutes. Its first product is a rapid urine self-test for the four most common sexually transmitted diseases, addressing the urgent need for timely diagnosis, as one million new STDs are diagnosed daily. Traditional testing often requires lab work and can take up to seven days for results. Testmate Health's all-in-one kit is designed for ease of use, allowing users to obtain immediate results that can be scanned by a smartphone for quick access to treatment if necessary. The company is also working on additional test kits for other diseases, aiming to empower individuals to manage their health conveniently from home.

Swiss Medical Union SA, founded in 2019 and based in Yverdon-les-Bains, Switzerland, specializes in healthcare technology focused on testing the interaction, efficiency, and safety of new medical products. The company manufactures Micro-Bioreactor equipment that allows for ex vivo testing with human organ and tissue models, enabling the selection of appropriate therapies tailored to individual patient needs. Additionally, Swiss Medical Union develops software that simulates organ activity, analyzes interactions between medical products and specific organs, and monitors real-time effects of treatments within the circulatory system. The company also provides clinical testing services aimed at supporting healthcare professionals in making informed clinical decisions, particularly in cancer treatment. Its offerings are designed to enhance therapeutic outcomes while minimizing the risks associated with unnecessary treatments.

Frater.swiss specializes in the development and production of innovative devices and applications designed for out-of-hospital care, specifically targeting hypothermic patients. Their products are utilized by healthcare professionals in high-pressure environments, including emergency medicine, expedition medicine, military medicine, and veterinary medicine. The company's focus is on creating efficient solutions for measuring hypothermia and stabilizing patient temperature through warm infusion, ultimately enhancing the quality of care in critical situations. By equipping medical personnel with advanced tools, Frater.swiss aims to improve patient outcomes and facilitate life-saving interventions in emergencies.

4i Labs generates multiplexed images of biological samples for molecular view of tumours.

Frater.swiss specializes in the development and production of innovative devices and applications designed for out-of-hospital care, specifically targeting hypothermic patients. Their products are utilized by healthcare professionals in high-pressure environments, including emergency medicine, expedition medicine, military medicine, and veterinary medicine. The company's focus is on creating efficient solutions for measuring hypothermia and stabilizing patient temperature through warm infusion, ultimately enhancing the quality of care in critical situations. By equipping medical personnel with advanced tools, Frater.swiss aims to improve patient outcomes and facilitate life-saving interventions in emergencies.

Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.

ALAnostics is a biopharmaceutical company that specializes in oncodiagnostics, originating as a spin-off from the University of Geneva. The company focuses on developing innovative tumour painting technology designed to assist surgeons in the real-time identification and removal of breast cancer during surgery. By utilizing nanomedicines for fluorescence-guided surgery, along with 5-ALA prodrugs for photodynamic therapy and light-activated antimicrobials, ALAnostics aims to enhance the accuracy of tumor removal, ultimately improving patient outcomes and saving lives.

B-rayZ is a spin-off from the University Hospital Zurich, focused on enhancing radiology through advanced technology. The team comprises experienced radiologists, data scientists, and physicians with over 15 years of expertise in medical imaging. B-rayZ develops artificial intelligence-based software that aids radiologists in mammography by offering real-time assessments of image quality and breast density. This innovative software enables accurate and standardized evaluations of medical imaging data, thereby improving breast cancer detectability. By providing intelligent tools, B-rayZ supports radiologists in enhancing their diagnostic capabilities while also contributing to reduced healthcare costs.

DIANA develops new dosimeters for radio diagnostic applications (especially interventional radiology) based on technology developed for high energy physics experiments

Frater.swiss specializes in the development and production of innovative devices and applications designed for out-of-hospital care, specifically targeting hypothermic patients. Their products are utilized by healthcare professionals in high-pressure environments, including emergency medicine, expedition medicine, military medicine, and veterinary medicine. The company's focus is on creating efficient solutions for measuring hypothermia and stabilizing patient temperature through warm infusion, ultimately enhancing the quality of care in critical situations. By equipping medical personnel with advanced tools, Frater.swiss aims to improve patient outcomes and facilitate life-saving interventions in emergencies.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

MOMM Diagnostics is a Swiss company founded in 2018 and headquartered in Basel. It specializes in the development of an in-vitro diagnostic test aimed at the early diagnosis of preeclampsia, a serious condition that can affect pregnant women. The company's innovative diagnostic device is designed for use at the point of care, allowing for quicker diagnosis and intervention, thereby improving patient outcomes. By focusing on women's health, MOMM Diagnostics aims to provide essential support to healthcare providers and enhance the care of pregnant women experiencing potential complications.

DIANA develops new dosimeters for radio diagnostic applications (especially interventional radiology) based on technology developed for high energy physics experiments

Clemedi AG develops innovative diagnostic workflows for infectious diseases, focusing on in vitro diagnostic tests that leverage next-generation sequencing and machine learning technologies. Established in 2018 and headquartered in Schlieren, Switzerland, the company aims to combat antibiotic resistance, which is projected to cause 10 million deaths annually by 2050. Clemedi's test kits are designed to diagnose drug-resistant infections directly from patient samples within a day, thereby enhancing doctors' decision-making and facilitating timely, personalized antibiotic therapies. By providing comprehensive information for targeted treatment, Clemedi strives to reduce antibiotic consumption and slow the spread of resistance, ultimately benefiting patients suffering from infectious diseases.

Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

Mirrakoi SA is a Swiss company established in 2018 and is a spin-off from the Swiss Federal Institute of Technology in Lausanne. It specializes in developing computer-aided design software, particularly focused on the medical field. The company's flagship product, Rhino3DMedical, facilitates a seamless workflow that allows users to view, analyze, and segment medical images, ultimately enabling the creation of 3D-printable meshes and CAD models from CT and MRI scans. This proprietary software is designed with a user-friendly interface, making it accessible for orthopedic surgical planning and the production of patient-specific anatomical models. Mirrakoi's innovative technology streamlines the process of generating anatomical 3D prints, enhancing both efficiency and precision in medical applications.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

IDUN Technologies AG is a Swiss neurotechnology startup founded in 2017, specializing in the design and manufacture of advanced biosensors for wearable devices. The company’s flagship product, DRYODES, features dry conductive electrodes that facilitate bio-potential monitoring, including electrocardiography (ECG), electroencephalography (EEG), and electromyography (EMG). IDUN Technologies aims to integrate neuroscience into everyday products, allowing connected devices to understand and respond to users' emotional needs through real-time neuro-markers. By developing innovative biosensor technology and a comprehensive neurofeedback value chain—from electrode manufacturing to product integration—IDUN enables industries to harness brain signal monitoring for enhanced user experiences. The company's Guardian Neuro-Intelligence Platform exemplifies this approach, utilizing in-ear EEGs to provide actionable insights that improve product design and interaction. Through this integration of emotion intelligence and connected devices, IDUN Technologies aspires to foster a more connected and empathetic world.

Clemedi AG develops innovative diagnostic workflows for infectious diseases, focusing on in vitro diagnostic tests that leverage next-generation sequencing and machine learning technologies. Established in 2018 and headquartered in Schlieren, Switzerland, the company aims to combat antibiotic resistance, which is projected to cause 10 million deaths annually by 2050. Clemedi's test kits are designed to diagnose drug-resistant infections directly from patient samples within a day, thereby enhancing doctors' decision-making and facilitating timely, personalized antibiotic therapies. By providing comprehensive information for targeted treatment, Clemedi strives to reduce antibiotic consumption and slow the spread of resistance, ultimately benefiting patients suffering from infectious diseases.

REM Analytics accurately addresses the Microtype of people for the microbiome industry. The company provides this measurement as an analytical service allowing customers to improve the impact of their products. The company has the unique capability to measure the colonization of specific probiotic strain in the microbiome of people. It can also measure the effectiveness of these strains on the micro type at large, as well as differences induced by changes in food and lifestyle. The company's objective is to allow the development of Evidence-based, personalized microbiome-based treatments.

Mirrakoi SA is a Swiss company established in 2018 and is a spin-off from the Swiss Federal Institute of Technology in Lausanne. It specializes in developing computer-aided design software, particularly focused on the medical field. The company's flagship product, Rhino3DMedical, facilitates a seamless workflow that allows users to view, analyze, and segment medical images, ultimately enabling the creation of 3D-printable meshes and CAD models from CT and MRI scans. This proprietary software is designed with a user-friendly interface, making it accessible for orthopedic surgical planning and the production of patient-specific anatomical models. Mirrakoi's innovative technology streamlines the process of generating anatomical 3D prints, enhancing both efficiency and precision in medical applications.

IDUN Technologies AG is a Swiss neurotechnology startup founded in 2017, specializing in the design and manufacture of advanced biosensors for wearable devices. The company’s flagship product, DRYODES, features dry conductive electrodes that facilitate bio-potential monitoring, including electrocardiography (ECG), electroencephalography (EEG), and electromyography (EMG). IDUN Technologies aims to integrate neuroscience into everyday products, allowing connected devices to understand and respond to users' emotional needs through real-time neuro-markers. By developing innovative biosensor technology and a comprehensive neurofeedback value chain—from electrode manufacturing to product integration—IDUN enables industries to harness brain signal monitoring for enhanced user experiences. The company's Guardian Neuro-Intelligence Platform exemplifies this approach, utilizing in-ear EEGs to provide actionable insights that improve product design and interaction. Through this integration of emotion intelligence and connected devices, IDUN Technologies aspires to foster a more connected and empathetic world.

ReflectUS develops a new diagnostic device for breast cancer diagnosis based on innovations in ultrasound imaging.

IDUN Technologies AG is a Swiss neurotechnology startup founded in 2017, specializing in the design and manufacture of advanced biosensors for wearable devices. The company’s flagship product, DRYODES, features dry conductive electrodes that facilitate bio-potential monitoring, including electrocardiography (ECG), electroencephalography (EEG), and electromyography (EMG). IDUN Technologies aims to integrate neuroscience into everyday products, allowing connected devices to understand and respond to users' emotional needs through real-time neuro-markers. By developing innovative biosensor technology and a comprehensive neurofeedback value chain—from electrode manufacturing to product integration—IDUN enables industries to harness brain signal monitoring for enhanced user experiences. The company's Guardian Neuro-Intelligence Platform exemplifies this approach, utilizing in-ear EEGs to provide actionable insights that improve product design and interaction. Through this integration of emotion intelligence and connected devices, IDUN Technologies aspires to foster a more connected and empathetic world.

ReflectUS develops a new diagnostic device for breast cancer diagnosis based on innovations in ultrasound imaging.

MesenFlow Technologies specializes in bio-imaging technology aimed at enhancing drug and cosmetic development. The company has created a platform that accelerates the drug development process by addressing challenges related to species cross-reactivity, animal testing, and understanding human diseases. Utilizing proprietary protocols on primary human cells, MesenFlow enables early definition of a drug's mechanism of action and translational relevance. The technology has also been adapted for the cosmetics and nutrition sectors, allowing for the assessment of the physiological impact of cosmetic or nutraceutical candidates during the early development phase. This approach supports environments where animal-free testing is essential and emphasizes the importance of understanding human biology in product development.

Komed Health offers a secure messaging platform designed to enhance communication among medical teams and between healthcare professionals and patients. This application streamlines and organizes real-time communication, replacing traditional methods like phones, pagers, and emails. It integrates seamlessly with existing clinical systems, facilitating integrated care pathways and enabling better decision-making by allowing physicians and nurses to access and share vital medical information at the point of care. The company collaborates closely with healthcare providers to develop features that cater specifically to the needs of modern healthcare professionals and workflows, aiming to improve care delivery through efficient and intelligent communication.

Sleepiz AG, based in Zurich, Switzerland, specializes in manufacturing a non-contact sleep monitoring device aimed at enhancing healthcare accessibility in home environments. Incorporated in 2018, the company's innovative product is designed to be placed on a bedside table, where it accurately measures patients' breathing patterns, heart rate, and body movements using advanced wireless millimeter wave technology and artificial intelligence. This device not only facilitates the diagnosis of sleep disorders but also enables long-term monitoring of chronic diseases, allowing healthcare providers to track patient progression and implement timely interventions for improved treatment outcomes. Through its user-friendly and precise approach, Sleepiz is positioned to significantly contribute to patient-centric disease management.

Immunas develops a point-of-care diagnostic device that within minutes will be able to determine if the source of infection is bacterial or viral. This will lead to informed antibiotic treatment decisions and reduce the number of avoidable deaths in societies due to antimicrobial resistance. Immunas is a med-tech start-up aiming to develop a rapid test allowing doctors to accurately distinguish the sources of infection. The test reduces antibiotic overuse and helps minimize antibiotic resistance. Patients receive optimal treatment faster with the test. Unlike traditional procedures that take hours to days to complete, Immunas' cutting edge chip-based technology, within minutes, will be able to accurately determine whether the cause of infection is bacterial or viral. Together with cost-effectiveness, ease-of-use, minimal invasiveness for the patient and immense potential impact on pressing public health concerns, we genuinely hope to enable smart and responsible use of antibiotics for the benefits of patients and for societies at large.

Kinastic AG, based in Winterthur, Switzerland, specializes in digital solutions for the fitness and wellness market. Founded in 2016, the company offers a multi-industry platform that connects organizations with their communities to promote health and fitness among employees and clients. Kinastic provides two main products: Kinastic Club, which facilitates the creation and sharing of personalized workout programs, and Kinastic Coach, an AI-driven virtual personal trainer that develops individualized training plans. This digital health management tool aims to support enterprises in enhancing employee well-being by offering tailored workout planning, progress tracking, and motivational reminders, thereby fostering a holistic approach to health and wellness within organizations.

PharmaBiome is specialized in the isolation, characterization, and technology of novel intestinal microbes. Their technology platform optimizes the lean and efficient development and production of defined, function-based microbiome therapies to treat intestinal diseases. PharmaBiome’s proprietary development pipeline allows a fast translation from the identification of mode of action to a product ready for clinics, using tailored, ecologically sound bacterial mixtures.

PharmaBiome is specialized in the isolation, characterization, and technology of novel intestinal microbes. Their technology platform optimizes the lean and efficient development and production of defined, function-based microbiome therapies to treat intestinal diseases. PharmaBiome’s proprietary development pipeline allows a fast translation from the identification of mode of action to a product ready for clinics, using tailored, ecologically sound bacterial mixtures.

PharmaBiome is specialized in the isolation, characterization, and technology of novel intestinal microbes. Their technology platform optimizes the lean and efficient development and production of defined, function-based microbiome therapies to treat intestinal diseases. PharmaBiome’s proprietary development pipeline allows a fast translation from the identification of mode of action to a product ready for clinics, using tailored, ecologically sound bacterial mixtures.

Xsensio is a digital health company focused on addressing the challenge of real-time, continuous monitoring of health parameters. It is developing an innovative Lab-on-Skin wearable device that serves as a miniaturized sensing platform, enabling continuous and real-time analysis of biochemical information at the skin's surface. This technology allows for the precise measurement of various health indicators, such as electrolytes, metabolites, hormones, and proteins, akin to traditional blood tests but in a minimally invasive manner. By providing unprecedented insights during critical health events, Xsensio aims to enhance patient care and shift the healthcare industry from a static to a dynamic approach in health monitoring.

SimplicityBio’s vision is to be one of the world’s leading biomarker discovery companies in the molecular diagnostic market, providing to our clients services and products based on robust signatures using multiple biomarkers. The company's range of services include biomarker discovery and ranking, signature creation, and existent signature improvement. Furthermore, it develops science, IP, and white paper technologies for its clients. SimplicityBio was founded in 2013 by Matthew Hall, Pedro Faustino, and Miguel Barreto and is based in Monthey.

Lunaphore specializes in tumor analysis through innovative microfluidic chip technology, which allows for rapid and precise assays that surpass traditional methods. The company's platform facilitates the extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology with a user-friendly interface. This technology aids researchers in immunology, immuno-oncology, and neurology by identifying clinically relevant biomarker signatures, which support the development of diagnostic tools and streamline clinical trials. By improving the efficiency of cancer diagnostics and enhancing the accuracy of results, Lunaphore ultimately aims to contribute to better patient outcomes.

Point-of-care testing for smoke poisoning.

Xsensio is a digital health company focused on addressing the challenge of real-time, continuous monitoring of health parameters. It is developing an innovative Lab-on-Skin wearable device that serves as a miniaturized sensing platform, enabling continuous and real-time analysis of biochemical information at the skin's surface. This technology allows for the precise measurement of various health indicators, such as electrolytes, metabolites, hormones, and proteins, akin to traditional blood tests but in a minimally invasive manner. By providing unprecedented insights during critical health events, Xsensio aims to enhance patient care and shift the healthcare industry from a static to a dynamic approach in health monitoring.

Lunaphore specializes in tumor analysis through innovative microfluidic chip technology, which allows for rapid and precise assays that surpass traditional methods. The company's platform facilitates the extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology with a user-friendly interface. This technology aids researchers in immunology, immuno-oncology, and neurology by identifying clinically relevant biomarker signatures, which support the development of diagnostic tools and streamline clinical trials. By improving the efficiency of cancer diagnostics and enhancing the accuracy of results, Lunaphore ultimately aims to contribute to better patient outcomes.

Calciscon AG is a Swiss diagnostic company based in Nidau, established in 2013. It specializes in developing and selling calcification blood test kits aimed at patients with chronic kidney diseases. The company's primary focus is on improving cardiovascular risk management for kidney patients through its calcification propensity diagnostics. Calciscon's testing services measure various indicators such as crystal formation time, serum magnesium, and fetuin-A levels, helping to identify individuals at elevated risk for pathological calcification. The company serves a diverse clientele, including researchers, clinical laboratories, and other companies, with the goal of becoming a leader in assessing, preventing, and treating biomineralization-related medical issues.

Medopticon / Panopticon is an innovative tumor analysis and classification platform.

Point-of-care testing for smoke poisoning.

Calciscon AG is a Swiss diagnostic company based in Nidau, established in 2013. It specializes in developing and selling calcification blood test kits aimed at patients with chronic kidney diseases. The company's primary focus is on improving cardiovascular risk management for kidney patients through its calcification propensity diagnostics. Calciscon's testing services measure various indicators such as crystal formation time, serum magnesium, and fetuin-A levels, helping to identify individuals at elevated risk for pathological calcification. The company serves a diverse clientele, including researchers, clinical laboratories, and other companies, with the goal of becoming a leader in assessing, preventing, and treating biomineralization-related medical issues.

Mabimmune AG is a healthcare company based in Schlieren, Switzerland, focused on developing immunotherapeutics for solid tumors. Founded in 2013, the company employs Reverse Translational Medicine to enhance the immune system's response against tumors. By targeting and modifying the cellular infiltrate within the tumor microenvironment, Mabimmune aims to improve patient outcomes, particularly in conjunction with checkpoint inhibitors. In addition to its oncology focus, the company also specializes in early diagnosis and targeted treatment to prevent heart attacks.

Qloudlab is a pioneering company known for inventing the world's first touchscreen-based biosensor. The company has developed Sceptre, a modular platform that enables multiple diagnostics at the Point-of-Care through a single, mobile device capable of conducting various tests, including blood, urine, saliva, and skin analyses. This innovative technology bridges the gap between smartphones, healthcare, and cloud solutions, offering a cost-effective approach to diagnostics. Complementing this, Loop Medical focuses on revolutionizing blood collection by providing a needleless, pain-free technology. This device collects blood samples using a proprietary cartridge that integrates seamlessly with standard laboratory processes, enhancing the convenience for both patients and healthcare professionals. Together, these innovations represent a significant advancement in accessible and efficient medical diagnostics.

Mabimmune AG is a healthcare company based in Schlieren, Switzerland, focused on developing immunotherapeutics for solid tumors. Founded in 2013, the company employs Reverse Translational Medicine to enhance the immune system's response against tumors. By targeting and modifying the cellular infiltrate within the tumor microenvironment, Mabimmune aims to improve patient outcomes, particularly in conjunction with checkpoint inhibitors. In addition to its oncology focus, the company also specializes in early diagnosis and targeted treatment to prevent heart attacks.

Mabimmune AG is a healthcare company based in Schlieren, Switzerland, focused on developing immunotherapeutics for solid tumors. Founded in 2013, the company employs Reverse Translational Medicine to enhance the immune system's response against tumors. By targeting and modifying the cellular infiltrate within the tumor microenvironment, Mabimmune aims to improve patient outcomes, particularly in conjunction with checkpoint inhibitors. In addition to its oncology focus, the company also specializes in early diagnosis and targeted treatment to prevent heart attacks.

Davos Diagnostics develops and produces systems for rapid testing. The small EVA-Systems are suited for a large variety of different analytical fields: Research IVD & Medical diagnostics Food quality control Environmental analysis Forensics Veterinary Quality control Davos Diagnostics EVA-System, is a unique rapid test system for quantitative tests, and will allow identifying multiple parameters in parallel with just a few drops of serum or plasma the patient. The sample is placed in the disposable EVA-Chip and measured in the small EVA-Reader instrument. The easy-to-use test kits (instrument, consumables, reagents) by Davos Diagnostics exploit the unique advantaged of the proprietary EVA-Biosensor Technology and will enable rapid, sensitive diagnostic tests. The small advanced optical EVA-Reader instrument, can be placed directly in every lab for decentralized quantitative biochemical testing at any place where needed by any person. This offers optimal, cost-effective workflow in research, quality control and analytical laboratories and – most important – with a few manipulation steps the results are available within 10 minutes.

SpiroChem AG, based in Basel, Switzerland, specializes in the design, synthesis, production, and commercialization of fine chemicals for drug discovery. Founded in 2011, the company offers a diverse range of novel building blocks, including bicyclo[1.1.1]pentanes, cubanes, oxetanes, spirocycles, and various other molecular fragments. These products are essential for pharmaceutical, agrochemical, and life science companies, aiming to enhance drug design and accelerate research initiatives. SpiroChem utilizes advanced process chemistry technologies and provides services such as proprietary screening of covalent fragments, fragment-based drug design, and computational-aided drug design. The company has established a global network of distributors and collaborates with numerous leading pharmaceutical organizations, enabling clients to improve drug efficacy and optimize lead compounds in their development programs.

BioScript revolutionized the prescription process, enabling healthcare providers to streamline service delivery. The platform has significantly reduced prescription errors, increased patient safety, and improved the overall healthcare experience. It develops cutting-edge biometric technology to enhance safety and convenience in healthcare operations, quickly establishing our presence in the industry.

Calosens is developing an analytical device for the in-vitro-diagnostics market that allows to analyse probes much faster, more sensitive (+/- 3nW) and more specific. In cases of bacterial infections (Meningitis/Sepsis) there is still a high mortality rate of up to 30% as the adequate medication and dose can not be appointed fast enough. This will improve with our device resulting in higher survival rates and reducing the risks of building new antibiotic resistance.

Malcisbo develops novel carbohydrate-based vaccines for human and animal health. Their focus is on parasitic diseases, on human food safety and on zoonotic diseases. The company has developed its proprietary target discovery platform to identify carbohydrates as vaccine targets. Combined with their glycoengineering technologies, novel and efficient glycoconjugate vaccines are being developed. Malcisbo is developing a strong pipeline of novel vaccine products coming out this platform for unmet needs in human and veterinary medicine targeting large markets. It is Malcisbo’s goal to develop affordable vaccines to protect people in underdeveloped areas against parasitic worm infections (e.g., helminthic infections by hookworm, filaria or schistosoma).

BioScript revolutionized the prescription process, enabling healthcare providers to streamline service delivery. The platform has significantly reduced prescription errors, increased patient safety, and improved the overall healthcare experience. It develops cutting-edge biometric technology to enhance safety and convenience in healthcare operations, quickly establishing our presence in the industry.

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage BARD1 autoantibody tests for early detection of lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer. Additional diagnostic projects are being evaluated for prostate, breast and other cancers. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.

YouRehab Ltd. specializes in developing innovative rehabilitation devices aimed at enhancing patient independence during recovery. Founded in 2010 and based in Zurich, Switzerland, the company offers products like YouGrabber, which focuses on upper limb rehabilitation, and YouKicker, designed for lower limb therapy. These devices utilize advanced sensor technology and gamification techniques to motivate patients, enabling them to engage in more intensive and successful rehabilitation. YouRehab acts as a connector between electronic portable devices and interactive training games available on smartphones, facilitating data exchange with a web platform. By collaborating with a network of academic, technology, and clinical partners, the company remains at the forefront of rehabilitation technology development. As of November 2017, YouRehab operates as a subsidiary of Reha-Stim Medtec GmbH & Co. KG.

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage BARD1 autoantibody tests for early detection of lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer. Additional diagnostic projects are being evaluated for prostate, breast and other cancers. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.

Powersens is a company that develops and sells a mobile solution featuring smart electronic shoe insoles. These insoles are designed to address orthopedic ailments by collecting foot data through pressure sensors embedded within the shoe. The technology provides biofeedback and analysis, helping users to monitor their walking patterns and prevent potential orthopedic complications. By integrating innovative sensor technology into footwear, Powersens aims to enhance foot health and improve overall mobility for its users.

Malcisbo develops novel carbohydrate-based vaccines for human and animal health. Their focus is on parasitic diseases, on human food safety and on zoonotic diseases. The company has developed its proprietary target discovery platform to identify carbohydrates as vaccine targets. Combined with their glycoengineering technologies, novel and efficient glycoconjugate vaccines are being developed. Malcisbo is developing a strong pipeline of novel vaccine products coming out this platform for unmet needs in human and veterinary medicine targeting large markets. It is Malcisbo’s goal to develop affordable vaccines to protect people in underdeveloped areas against parasitic worm infections (e.g., helminthic infections by hookworm, filaria or schistosoma).

ProteoMediX is a healthcare company focused on improving the diagnosis of prostate cancer through innovative biomarker signatures. Based in the Bio-Technopark of Zurich-Schlieren, Switzerland, the company has developed Proclarix®, a blood-based test panel that assesses the risk of prostate cancer and is currently available in Europe. This test aims to aid in the early detection of prostate cancer and provide insights into the cancer's stage, allowing for improved treatment strategies. By offering enhanced accuracy in distinguishing between aggressive and indolent cancers, ProteoMediX seeks to support physicians in making better-informed decisions for patient care.

InSphero AG specializes in the development of organotypic biological 3D microtissues and microtissue-based assays, aimed at enhancing in vitro testing for drug discovery and toxicity assessment. Founded in 2009 and headquartered in Schlieren, Switzerland, the company provides a variety of products including liver, pancreas, and tumor microtissues, as well as custom-made microtissues and specialized kits. InSphero's 3D cell culture platforms, such as the GravityTRAP ultra-low attachment plate, facilitate the generation and analysis of scaffold-free 3D microtissue spheroids. Their offerings also extend to cytotoxicity assay kits and services for hepatotoxicity testing, cancer research, and stem cell applications. The technology developed by InSphero enables researchers to obtain biologically relevant insights, improving the predictive power of drug testing and reducing reliance on animal testing.

ProteoMediX is a healthcare company focused on improving the diagnosis of prostate cancer through innovative biomarker signatures. Based in the Bio-Technopark of Zurich-Schlieren, Switzerland, the company has developed Proclarix®, a blood-based test panel that assesses the risk of prostate cancer and is currently available in Europe. This test aims to aid in the early detection of prostate cancer and provide insights into the cancer's stage, allowing for improved treatment strategies. By offering enhanced accuracy in distinguishing between aggressive and indolent cancers, ProteoMediX seeks to support physicians in making better-informed decisions for patient care.

YouRehab Ltd. specializes in developing innovative rehabilitation devices aimed at enhancing patient independence during recovery. Founded in 2010 and based in Zurich, Switzerland, the company offers products like YouGrabber, which focuses on upper limb rehabilitation, and YouKicker, designed for lower limb therapy. These devices utilize advanced sensor technology and gamification techniques to motivate patients, enabling them to engage in more intensive and successful rehabilitation. YouRehab acts as a connector between electronic portable devices and interactive training games available on smartphones, facilitating data exchange with a web platform. By collaborating with a network of academic, technology, and clinical partners, the company remains at the forefront of rehabilitation technology development. As of November 2017, YouRehab operates as a subsidiary of Reha-Stim Medtec GmbH & Co. KG.

InSphero AG specializes in the development of organotypic biological 3D microtissues and microtissue-based assays, aimed at enhancing in vitro testing for drug discovery and toxicity assessment. Founded in 2009 and headquartered in Schlieren, Switzerland, the company provides a variety of products including liver, pancreas, and tumor microtissues, as well as custom-made microtissues and specialized kits. InSphero's 3D cell culture platforms, such as the GravityTRAP ultra-low attachment plate, facilitate the generation and analysis of scaffold-free 3D microtissue spheroids. Their offerings also extend to cytotoxicity assay kits and services for hepatotoxicity testing, cancer research, and stem cell applications. The technology developed by InSphero enables researchers to obtain biologically relevant insights, improving the predictive power of drug testing and reducing reliance on animal testing.

Compliant Concept AG, based in Dübendorf, Switzerland, specializes in developing advanced bed systems aimed at the treatment and prevention of pressure ulcers. Founded in 2009 as a spinoff from the Empa and ETH Zurich, the company leverages technology to enhance patient care in hospitals and nursing homes. Its intelligent bed systems incorporate mobility monitors that assess clinical risks and identify factors influencing pressure ulcer development, such as medication and pre-bedtime activities. By automating routine tasks, Compliant Concept's solutions help reduce the workload of healthcare professionals, allowing them to focus on providing better care to patients while improving overall comfort and efficiency in healthcare settings.

InSphero AG specializes in the development of organotypic biological 3D microtissues and microtissue-based assays, aimed at enhancing in vitro testing for drug discovery and toxicity assessment. Founded in 2009 and headquartered in Schlieren, Switzerland, the company provides a variety of products including liver, pancreas, and tumor microtissues, as well as custom-made microtissues and specialized kits. InSphero's 3D cell culture platforms, such as the GravityTRAP ultra-low attachment plate, facilitate the generation and analysis of scaffold-free 3D microtissue spheroids. Their offerings also extend to cytotoxicity assay kits and services for hepatotoxicity testing, cancer research, and stem cell applications. The technology developed by InSphero enables researchers to obtain biologically relevant insights, improving the predictive power of drug testing and reducing reliance on animal testing.

Compliant Concept AG, based in Dübendorf, Switzerland, specializes in developing advanced bed systems aimed at the treatment and prevention of pressure ulcers. Founded in 2009 as a spinoff from the Empa and ETH Zurich, the company leverages technology to enhance patient care in hospitals and nursing homes. Its intelligent bed systems incorporate mobility monitors that assess clinical risks and identify factors influencing pressure ulcer development, such as medication and pre-bedtime activities. By automating routine tasks, Compliant Concept's solutions help reduce the workload of healthcare professionals, allowing them to focus on providing better care to patients while improving overall comfort and efficiency in healthcare settings.